Literature DB >> 31990420

Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.

Lukas Macke1, Christian Schulz1, Leandra Koletzko1, Peter Malfertheiner1,2.   

Abstract

BACKGROUND: Proton pump inhibitors (PPI) are widely used to treat acid-related disorders of the upper gastrointestinal tract. However, large observational studies have raised concerns about PPI-associated adverse events. In recent years, data from next-generation sequencing studies suggested that PPIs affect the composition of the intestinal microbiota, while a balanced gut microbiome is essential for maintaining health. AIM: To review the available evidence from next-generation sequencing studies on the effect of PPIs on the intestinal microbiome and to discuss possible implications of PPI-induced dysbiosis in health and disease.
METHODS: A systematic review was conducted following the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. A PubMed query yielded 197 results. 19 publications met the prespecified eligibility criteria.
RESULTS: Twelve observational study cohorts with 708 PPI users and 11 interventional cohorts with 180 PPI users were included in the review. In most studies, PPI treatment did not affect microbiological richness and diversity, but was associated with distinct taxonomic alterations: In the upper gastrointestinal tract, PPI users showed overgrowth of orally derived bacteria, mostly Streptococcaceae (findings based on six independent cohorts with 126 PPI users). In faecal samples, PPIs increased multiple taxa from the orders Bacillales (eg, Staphylococcaceae), Lactobacillales (eg, Enterococcaceae, Lactobacillaceae, Streptococcaceae) and Actinomycetales (eg, Actinomycetaceae, Micrococcaceae), the families Pasteurellaceae and Enterobacteriaceae and the genus Veillonella. Taxa decreased by PPIs include Bifidobacteriaceae, Ruminococcaceae, Lachnospiraceae and Mollicutes (findings in faecal samples based on 19 independent cohorts with 790 PPI users).
CONCLUSION: PPI use is associated with moderate alterations to upper and distal gut microbiota. The available data suggest that PPI-induced hypochlorhydria facilitates colonization of more distal parts of the digestive tract by upper gastrointestinal microbiota.
© 2020 John Wiley & Sons Ltd.

Entities:  

Year:  2020        PMID: 31990420     DOI: 10.1111/apt.15604

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole.

Authors:  Wenjun Liu; Yong Xie; Yingmeng Li; Longjin Zheng; Qiuping Xiao; Xu Zhou; Qiong Li; Ni Yang; Kexuan Zuo; Tielong Xu; Nong-Hua Lu; Heping Zhang
Journal:  BMC Gastroenterol       Date:  2022-05-20       Impact factor: 2.847

2.  Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure.

Authors:  Ke Wang; Zhao Zhang; Zhi-Shuo Mo; Xiao-Hua Yang; Bing-Liang Lin; Liang Peng; Yang Xu; Chun-Yan Lei; Xiao-Dong Zhuang; Ling Lu; Rui-Fu Yang; Tao Chen; Zhi-Liang Gao
Journal:  Gut Microbes       Date:  2021 Jan-Dec

3.  Influence of Factors Altering Gastric Microbiota on Bariatric Surgery Metabolic Outcomes.

Authors:  Eduardo García-Fuentes; Francisco J Tinahones; Carolina Gutiérrez-Repiso; Isabel Moreno-Indias; Gracia M Martín-Núñez; Ailec Ho-Plagaro; Luis Ocaña-Wilhelmi; Diego Fernández García; Montserrat Gonzalo Marín; Francisco J Moreno-Ruiz
Journal:  Microbiol Spectr       Date:  2021-11-17

4.  Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis.

Authors:  Jonas Sagard; Tor Olofsson; Elisabeth Mogard; Jan Marsal; Kristofer Andréasson; Mats Geijer; Lars Erik Kristensen; Elisabet Lindqvist; Johan K Wallman
Journal:  Arthritis Res Ther       Date:  2022-02-12       Impact factor: 5.156

5.  Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.

Authors:  Karla A Lee; Andrew Maltez Thomas; Laura A Bolte; Johannes R Björk; Laura Kist de Ruijter; Federica Armanini; Francesco Asnicar; Aitor Blanco-Miguez; Ruth Board; Neus Calbet-Llopart; Lisa Derosa; Nathalie Dhomen; Kelly Brooks; Mark Harland; Mark Harries; Emily R Leeming; Paul Lorigan; Paolo Manghi; Richard Marais; Julia Newton-Bishop; Luigi Nezi; Federica Pinto; Miriam Potrony; Susana Puig; Patricio Serra-Bellver; Heather M Shaw; Sabrina Tamburini; Sara Valpione; Amrita Vijay; Levi Waldron; Laurence Zitvogel; Moreno Zolfo; Elisabeth G E de Vries; Paul Nathan; Rudolf S N Fehrmann; Véronique Bataille; Geke A P Hospers; Tim D Spector; Rinse K Weersma; Nicola Segata
Journal:  Nat Med       Date:  2022-02-28       Impact factor: 87.241

6.  Proton pump inhibitors induce changes in the gut microbiome composition of systemic lupus erythematosus patients.

Authors:  Xian-Bao Li; Xiu-Jie Chu; Nv-Wei Cao; Hua Wang; Xin-Yu Fang; Yin-Guang Fan; Bao-Zhu Li; Dong-Qing Ye
Journal:  BMC Microbiol       Date:  2022-04-27       Impact factor: 4.465

7.  A Long Duration of Reflux Symptoms is the Predominant Risk Factor for Depression in Vietnamese Patients with Gastroesophageal Reflux Disease.

Authors:  Duc Trong Quach; Binh Thanh Phan
Journal:  Neuropsychiatr Dis Treat       Date:  2022-09-23       Impact factor: 2.989

8.  Developmental intestinal microbiome alterations in canine fading puppy syndrome: a prospective observational study.

Authors:  Smadar Tal; Evgenii Tikhonov; Omry Koren; Sharon Kuzi; Itamar Aroch; Lior Hefetz; Sondra Turjeman
Journal:  NPJ Biofilms Microbiomes       Date:  2021-06-23       Impact factor: 7.290

9.  Effects of proton pump inhibitor use on the esophageal microbial community.

Authors:  Sadia Tasnim; Aaron L Miller; Daniel C Jupiter; Catherine F Hamilton; Gabriel L Reep; Timothy S Krill; Richard B Pyles; Ikenna C Okereke
Journal:  BMC Gastroenterol       Date:  2020-09-23       Impact factor: 3.067

Review 10.  Gut microbiota-mediated immunomodulation in tumor.

Authors:  Xinyi Liu; Yanjie Chen; Si Zhang; Ling Dong
Journal:  J Exp Clin Cancer Res       Date:  2021-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.